Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by ...
Beyond wanting to create more effective drugs, the motivations for constant attempts to produce new, non-opioid painkillers are largely either commercial — because opioid availability is limited ...
The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say Journavx is an important alternative because the power of opioids helped fuel an ...
And the big headline here is that it’s not an opioid, and it’s non-addictive. So how does it work? Who should take it? Does it signal a new era for pain medication? Here to help break down this new ...
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency has approved in over two decades. Because of their ...